Table 2.
Economically justifiable price at target WTP of CHF100 000/QALY
| Treatment | Discount level of pack prices | Costs (CHF) | QALYs | ΔCosts (CHF) | ΔQALYs | Comment | ICERs (CHF/QALY gained) | Total drug costs (CHF) |
|---|---|---|---|---|---|---|---|---|
| Overall population (carboplatin) | ||||||||
| For Nivo and Ipi | ||||||||
| Pem+Platin | 69,345 | 1.20 | 12,442 | |||||
| Nivo+Ipi | −52% (to 48%) | 125,132 | 1.76 | 55,787 | 0.56 | Cost effective at WTP vs Pem+Platin | 99,128 | 58,707 |
| Pem+Platin+Beva | 163,441 | 1.56 | 38,309 | −0.20 | Absolutely dominated | 92,937 | ||
| For bevacizumab | ||||||||
| Pem+Platin | 76,138 | 1.20 | 19,235 | |||||
| Pem+Platin+Beva | −72% (to 28%) | 112,099 | 1.56 | 35,961 | 0.36 | Cost effective at WTP vs Pem+Platin | 99,928 | 41,595 |
| Epithelioid population (carboplatin) | ||||||||
| For Nivo and Ipi | ||||||||
| Pem+Platin | 68,578 | 1.44 | 10,001 | |||||
| Nivo+Ipi | −73% (to 27%) | 99,606 | 1.75 | 31,028 | 0.32 | Cost effective at WTP | 97,877 | 33,517 |
| Pem+Platin+Beva | 205,983 | 1.95 | 106,377 | 0.20 | 541,636 | 128,999 | ||
| For bevacizumab | ||||||||
| Pem+Platin | 78,693 | 1.44 | 20,116 | |||||
| Pem+Platin+Beva | −72% (to 28%) | 129,529 | 1.95 | 50,837 | 0.51 | 99,017 | 52,546 | |
| Nivo+Ipi | 180,101 | 1.75 | 50,572 | −0.20 | Absolutely dominated | 114,013 | ||
Beva bevacizumab, CHF Swiss Francs, ICER incremental cost-effectiveness ratio, ipi ipilimumab, nivo nivolumab, pem pemetrexed, QALY quality-adjusted life-year, WTP willingness-to-pay